February 27, 2026
Headlines

Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?

01 mins

Chimerix plans to submit an NDA for dordaviprone to treat H3 K27M-mutant glioma, with potential U.S. FDA approval targeted for late 2025.

read more

Leave a Reply

Your email address will not be published. Required fields are marked *

Related News